In China, a vaccine to protect against the new Novel Coronavirus disease Code 19 is available for emergency use until September, while it may be available to the general public early next year.
This is the first time Chinese medical officials have estimated the timing of the corona virus vaccine.
Earlier, the US Food and Drug Administration estimated that a vaccine would take at least a year to develop, while the World Health Organization said it would take 12 to 18 months to develop a vaccine.
However, Oxford University in the United Kingdom is also committed to developing a vaccine by September, and a human trial has begun this week.
Gao Fu, head of China’s Center for Disease Control and Prevention, told China Global Television Network on Thursday that clinical trials of the vaccine in the country are currently in the second or third phase and that they may be in the second wave of the epidemic. May be available up to
It should be noted that 3 vaccines are currently being developed in China and all three have completed the first phase of the trials.
Gao Fu said: “We are at the forefront of vaccine development and it is likely that a vaccine for emergency use will be ready by September. These new vaccines could be used for certain groups of people, such as medical workers.” ۔
“The vaccine is likely to be available to the general public early next year, but it will depend on progress in its preparation,” he said.
Shai Yai, a virologist at the Institute of Microbiology at the Chinese Academy of Sciences, said in a press briefing that unlike the influenza, the new novel corona virus does not undergo genetic changes very quickly and does not appear to be as common as seasonal flu.
“Some experts believe that this new virus will become part of normal life and spread like the influenza virus every year, but we believe that this possibility is very low, there is no evidence at this time that It should be noted that the new corona virus changes as quickly as the influenza virus.
He also ruled out the possibility that code 19 could become a chronic disease, as it grows mostly in the respiratory tract, as was the case with SARS and MERS.
It may be recalled that a major Chinese pharmaceutical company had invited the National Institutes of Health (NIH) Islamabad to conduct a clinical trial in Pakistan of a vaccine developed for Covid 19.
The offer was made in a letter written by the General Manager of China Signo Farm International Corporation to the Executive Director of NIH, Major General Dr. Amir Ikram.
The state-owned company caters to more than 80 percent of China’s immunization needs and has also played a key role in the fight against Covid 19.
The letter expressed the hope that “a successful trial would make Pakistan one of the first countries to introduce the Covid 19 vaccine.”
The Pakistani government has asked for more information on the possible trial of the vaccine.
Dr. Zafar Mirza, Special Assistant to the Prime Minister for Health, confirmed that a Chinese company had approached Pakistan for possible trials of the vaccine.
About vaccine for COVID-19: Pakistan is approached by Chinese company for possible trails. We have asked for more info which we will evaluate through relevant experts from safety, ethics, regulation & feasibility perspectives before deciding. Too early to say anything! <290>
— Zafar Mirza (@zfrmrza) April 24, 2020
A total of 6 vaccines worldwide have entered the human testing phase, while 77 are still in the early stages.
On Thursday, Oxford University began testing its vaccine on humans by injecting its dose into two volunteers.
The technology used to develop the vaccine is already being used in 10 different therapies, and research team leader Dr. Sarah Gilbert expects to use 1 million doses by September.
Similarly, in March in the United States, the Moderina company first started testing a vaccine on humans, while the trial of the vaccine of another company, Inouye, began earlier this month.
However, it is said that these vaccines can take one to one-and-a-half years to develop and be approved for general use.
Germany has also approved a human trial of the vaccine, which is expected to begin next week.
The vaccine has been dubbed BNT 162 and has been developed by two leading companies.
Another vaccine was tested on animals in China and found to protect monkeys from infection.
A company called Synovik Biotech said it injected two different doses of the vaccine into eight monkeys belonging to a species that is not at risk of extinction.
Three weeks later, they were exposed to the virus but did not become infected.
The company said in a statement that all monkeys were “largely protected from SARS-CoV-2 infection”